Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

Main Article Content

Kenneth B Gordon
Richard G Langley
Richard B Warren
Yukari Okubo
David Rosmarin
Mark Lebwohl
Luke Peterson
Cynthia Madden
Dirk de Cuyper
Natalie Nunez Gomez
Diamant Thaçi


bimekizumab, psoriasis, moderate to severe, phase 2, phase 3, clinical trial, pooled data




1. Glatt S et al. Ann Rheum Dis 2018;77:523–32

2. Adams R et al. Front Immunol 2020;11:1894

3. Warren RB et al. J Invest Dermatol 2015;135:2632–40

4. Gordon KB et al. JAMA Dermatol 2022;158(7):735–744

5. BE SURE (NCT03412747); BE VIVID (NCT03370133); BE READY (NCT03410992); BE BRIGHT (NCT03598790); BE ABLE 1 (NCT02905006); BE ABLE 2 (NCT03010527); PS0016 (NCT03025542); PS0018 (NCT03230292)

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>